Mr. Lafleur brings more than 25 year of experience in pharmaceutical and biotech industries as well as medical and clinical to Dracen. Prior to joining Dracen, Mr. Lafleur worked at several leading biopharmaceutical companies including Ipsen, Helsinn, Celgene, Pfizer, Genentech, Sanofi and Schering-Plough. He successfully launched eight products in the US and Europe in the areas of oncology, hepatology and rheumatology. Prior to his time in industry, Mr. Lafleur spent several years at New York University Cancer Center in academic research and administration roles. He holds a Master’s in Public Health from Columbia University Mailman School of Public Health in New York city and a BS in Immunology and Microbiology from McGill University in Montreal, Canada.
Dr. Dugan joined Dracen Pharmaceuticals in 2018 with 20 + years of experience as a senior leader, more recently as Senior Vice-President, in Novartis oncology global strategic drug development and portfolio management, including translational science, early and late clinical development, life cycle management and companion diagnostic development that resulted in several regulatory filings and approvals (Femara® and Ceritinib), including Breakthrough Therapy Designations. Direct experience with global health authorities including FDA, EMA and PMDA and national authorities. She led the Novartis Exploratory Oncology Development Group for five years which transitioned compounds from discovery to proof-of-concept in the clinic, including Tasigna. Dr. Dugan also held several development positions at Schering-Plough (now Merck & Co.), which led to the first approval of temozolomide for brain tumors and American Cyanamid (now Pfizer). Dr. Dugan received her BA and medical degrees and training in hematology and oncology from New York University.
A founding executive of Dracen, Dr. Ragab was most recently the Vice President, Search and Evaluation, Oncology at Bristol-Myers Squibb where he was involved in many major immuno-oncology deals. Prior to that, he was Global Partnering Head, Oncology at Hoffman-La Roche (member of the Roche Group) and prior to that global commercial leader for oncology at Pfizer. He also held various positions at Ortho Biotech and Schering-Plough (now Merck & Co.). He holds a Master Degree in Radiation Oncology from Cairo University School of Medicine and a Bachelor of Medicine and Surgery degree from Cairo University School of Medicine.
Mr. Bilski has more than 20 years of experience in accounting, finance, strategic planning, and executive management for public and private companies. Mr. Bilski was the Chief Financial Officer of Tragara Pharmaceuticals, Inc. from 2007-2018. Prior to Tragara, Mr. Bilski was the Director of Finance at Del Mar Database (DMD), a software and services provider for mortgage lenders. Mr. Bilski played a key role in leading DMD through a turnaround and rapid expansion and subsequent acquisition by Fiserv, Inc. Prior to DMD, Mr. Bilski spent five years at Arthur Andersen LLP in Washington, D.C., where he managed financial statement audits and due diligence engagements for various public and private companies. Mr. Bilski also spent two years with a consulting firm, where he worked exclusively with early-stage technology firms. Mr. Bilski graduated from The College of William and Mary with a BBA degree in Accounting.
Dr. Wild joined Dracen Pharmaceuticals in 2017 as one of the founding executives and Chief Scientific Officer (CSO). He is responsible for all discovery, preclinical development and translational research efforts of Dracen’s therapeutic pipeline and leads scientific strategy. Dr. Wild is a seasoned R&D executive with 20+ years of broad experience in drug discovery and development, spanning both small molecules and biologics. Throughout his career, Dr. Wild has contributed to the advancement of numerous clinical development candidates, including four FDA-approved oncology therapeutics (sunitinib, cetuximab, dasatinib and erlotinib). Before Dracen Pharmaceuticals, Dr. Wild was an independent consultant to biotech, pharma and venture capital companies. Prior to that, he served in various leadership roles including Chief Scientific Officer and Senior Vice President of Research at Ignyta, Inc. (now member of the Roche Group), Chief Scientific Officer Oncology Research at Eli Lilly & Company, Senior Director at OSI Pharmaceuticals (now a wholly owned subsidiary of Astellas Pharma), Senior Research Investigator at Bristol-Myers Squibb and Scientist at SUGEN, Inc. (acquired by Pfizer). Dr. Wild is a native of Germany and received his BS in Biochemistry and PhD in Pharmacology from the University of Minnesota, Minneapolis.
Mr. Estok brings 30+ years of experience in development and commercialization of pharmaceuticals to Dracen. Previously, he was the founding President/CEO of Tragara Pharmaceuticals, founding President/CEO of Cabrellis Pharmaceuticals where he led the organization’s development of amrubicin prior to its acquisition by Pharmion, and served as Chief Commercial Officer of Conforma Therapeutics whose HSP90 franchise was acquired by Biogen-Idec. A 19-year veteran of Schering-Plough, Mr. Estok held a number of positions with progressing responsibility in R&D (biochemistry and oncology operations management), in both US and global marketing, European operations, sales and commercial development. His most recent position was Vice President, US Marketing and Commercial Development, Oncology. Mr. Estok has led multidisciplinary R&D, business development, and commercial teams and is a recognized leader in the commercialization of oncology therapeutics and the formation/growth of new divisions and companies. Mr. Estok graduated from Virginia Tech with a BS degree in Biochemistry and was awarded an MBA from Fairleigh Dickinson University. He is currently a Board Director at Adastra Pharmaceuticals.